These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 10029002)

  • 21. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project.
    J Clin Oncol; 1991 Sep; 9(9):1668-74. PubMed ID: 1831495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Doxorubicin and paclitaxel versus 5-fluorouracil, doxorubicin and cyclophosphamide as first-line treatment in women with metastatic breast carcinoma: final results of a phase III multicenter randomized trial].
    Amadori D; Fabbri M
    Tumori; 2001; 87(5):A18-9. PubMed ID: 11765729
    [No Abstract]   [Full Text] [Related]  

  • 23. Paclitaxel doublets in metastatic breast cancer: Eastern Cooperative Oncology Group and Hoosier Oncology Group Studies.
    Sledge GW
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):57-9. PubMed ID: 8893901
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Meta-analysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma.
    Omura GA; Brady MF
    Obstet Gynecol; 1993 Apr; 81(4):641-2. PubMed ID: 8459984
    [No Abstract]   [Full Text] [Related]  

  • 25. Platinum compounds and paclitaxel in advanced epithelial ovarian cancer.
    Gadducci A; Brunetti I; Cosio S; Giannessi PG; Genazzani AR; Conte P
    Anticancer Res; 1997; 17(6D):4703-8. PubMed ID: 9494592
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer.
    Covens A; Carey M; Bryson P; Verma S; Fung Kee Fung M; Johnston M
    Gynecol Oncol; 2002 Apr; 85(1):71-80. PubMed ID: 11925123
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial.
    International Collaborative Ovarian Neoplasm Group
    Lancet; 2002 Aug; 360(9332):505-15. PubMed ID: 12241653
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Optimal therapeutic strategies in ovarian epithelial cancer in 1997].
    Piccart MJ; Nogaret JM
    Rev Med Brux; 1997 Sep; 18(4):198-203. PubMed ID: 9411642
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemotherapy for ovarian cancer.
    Parmar MK; Sandercock J
    N Engl J Med; 1996 May; 334(19):1268-9; author reply 1270. PubMed ID: 8606729
    [No Abstract]   [Full Text] [Related]  

  • 30. Chemotherapy for ovarian cancer.
    Cvitkovic E; Misset JL
    N Engl J Med; 1996 May; 334(19):1269; author reply 1270. PubMed ID: 8606730
    [No Abstract]   [Full Text] [Related]  

  • 31. Chemotherapy for ovarian cancer--trials, controversies and funding.
    Hawkins RE
    Br J Cancer; 1998 Dec; 78(11):1402-3. PubMed ID: 9836469
    [No Abstract]   [Full Text] [Related]  

  • 32. High versus low dose cisplatin in epithelial ovarian cancer.
    Ghersi D; Parmar MK; Guthrie D; Williams C
    Lancet; 1992 Sep; 340(8820):678-9. PubMed ID: 1355247
    [No Abstract]   [Full Text] [Related]  

  • 33. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens.
    Cantù MG; Buda A; Parma G; Rossi R; Floriani I; Bonazzi C; Dell'Anna T; Torri V; Colombo N
    J Clin Oncol; 2002 Mar; 20(5):1232-7. PubMed ID: 11870165
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group).
    McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
    Semin Oncol; 1996 Oct; 23(5 Suppl 12):40-7. PubMed ID: 8941409
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination regimens of paclitaxel and the platinum drugs as first-line regimens for ovarian cancer.
    Ozols RF
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):1-6. PubMed ID: 8643963
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: a gynecologic oncology group study.
    Almadrones L; McGuire DB; Walczak JR; Florio CM; Tian C
    Oncol Nurs Forum; 2004 May; 31(3):615-23. PubMed ID: 15146227
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current status and future directions of platinum/paclitaxel-based chemotherapy of ovarian cancer.
    Markman M
    Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-24-S11-27. PubMed ID: 9314295
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The case for combination chemotherapy in the treatment of advanced ovarian cancer.
    Ozols RF
    J Clin Oncol; 1985 Nov; 3(11):1445-7. PubMed ID: 3932603
    [No Abstract]   [Full Text] [Related]  

  • 39. Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer.
    Ozols RF
    Semin Oncol; 2000 Jun; 27(3 Suppl 7):3-7. PubMed ID: 10952119
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New therapy for ovarian cancer.
    Neijt JP
    N Engl J Med; 1996 Jan; 334(1):50-1. PubMed ID: 7494573
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.